Novavax vaccine: how well does the vaccine actually work against corona?

  • fromDominik Jahn


Novavax: The vaccine has not yet been approved in Europe. Nevertheless, the EU concludes contracts with manufacturers for over 100 million cans.

The booster wave is rolling out in Germany. Sufficient vaccine must be found. The current numbers in the coronavirus ticker from show the critical development. Also for first vaccinations. Now, with Novavax, a new type of vaccine could soon be approved in Europe. This progress can lead to rethinking, especially for vaccine skeptics. But how good is Novavax? How well does it protect against corona?

One of the advantages of Novavax is storage. As a protein vaccine, it can be stored and transported at refrigerator temperatures. Approval for the US manufacturer in the EU has been applied for – with a decision by the European Medicines Agency (EMA) is loud Wirtschaftswoche expected in a few weeks.

Novavax vaccine before approval: contract with EU since August

According to an earlier announcement from the EMA, a contract with the pharmaceutical company Novavax has been in place since August, which enables the European member states to purchase up to 100 million doses of the vaccine. At the time, Commission President Ursula von der Leyen said: “As new coronavirus variants are spreading in Europe and worldwide, this new contract with a company that is already successfully testing its vaccine on these variants is another safeguard to protect our population. It also strengthens our broad vaccine portfolio for the benefit of the people in Europe and our partners worldwide. “

Novovax: how well does the vaccination pot protect against corona?

The vaccine has not yet been approved. But like that Pharmaceutical Newspaper writes, the company has published the final study data for the “Phase III PREVENT-19 study”. Accordingly, only 14 vaccinated people in the study were mildly and none moderately or severely ill with Covid-19. The way to Europe now seems to be purely a matter of form.

The first successes were already apparent in mid-June. According to the study at the time, the vaccine’s effectiveness was 90.4 percent. This means that around 90 percent fewer corona diseases occurred in people who were vaccinated with the two-time vaccine than in the participants in the control group.

30,000 adults in the United States and Mexico participated in this third-phase study. When selecting the test subjects, according to the Pharmaceutical Newspaper Payed attention to different ethnicities as well as to people at high risk for severe Covid-19 courses.

Background to the study for the Novavax vaccine

The article resulted in “Two thirds of the participants received two vaccine doses 21 days apart, and one third received placebo injections according to the same vaccination schedule. A total of 77 symptomatic corona infections occurred, 14 among the vaccinated and 63 in the placebo group; most of them were triggered by the alpha variant (B.1.1.7). This corresponds to an effectiveness of 90.4 percent ”.

The protection against moderate and severe disease progression was even 100 percent in the end. With the new vaccine, however, the fear of side effects always comes back for many people. As reported that there were effects in the tests with the Nuvaxovid in isolated participants.

Novavax also with vaccination protection against corona variants

In another phase III study with around 15,000 participants in England, the Novavax vaccine was also able to prove itself against the then new variants of the coronavirus alpha and beta. According to the New England Journal of Medicine, the vaccine showed “an effectiveness of 89.7 percent protection against SARS-CoV-2 infection and showed a high effectiveness against the B.1.1.7 variant “.

Novavax vaccine approved in several countries

While you still have to wait for approval for Europe, the US company Novavax is already on the market in other countries and is inoculated. Indonesia was the first country in early November, followed by the Philippines in mid-November. As unteranderem writes, the manufacturer had already applied for approval for Great Britain at the end of October.

According to the report, the company has so far postponed the application for the American market. At the end of 2021, however, the FDA should also be there.

Rubric picture: © Tomislav Miletic / dpa

For Latest Updates Follow us on Google News

PREV Despite tensions, Edouard Philippe reaffirms his “loyalty” to Emmanuel Macron
NEXT LIVE – Vienna New Year’s Concert 2022: Here you can see the concert live – culture